New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction PeriodBusiness Wire • 10/24/22
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction TherapyBusiness Wire • 10/21/22
Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/19/22
Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC MelanomaBusiness Wire • 10/19/22
Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022Business Wire • 10/07/22
Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 TrialBusiness Wire • 10/04/22
Bristol Myers Sotyktu Approval Sends Ventyx Stock Soaring: Consider Buying BothSeeking Alpha • 09/23/22